A key tool for ensuring the stability of our shareholder base
Amid strong growth and an increasingly complex shareholder structure, TISSIUM chose Equify to ensure the reliability of its equity data management, automate its processes, and improve day-to-day efficiency.
-1.png)
"With Excel, every change carried the risk of an error. Equify has allowed us to move from rough management to reliable, traceable data that is accessible in real time."
About Tissium
TISSIUM is a medtech company based in Paris (France) and Cambridge (United States), with a production facility in Roncq (France). The company is developing a proprietary platform of fully biosynthetic, biomorphic, programmable, and elastomeric polymers designed to address unmet clinical needs in atraumatic tissue repair and reconstruction.
TISSIUM’s diversified portfolio includes one marketed product and six products in development, spanning three therapeutic areas: atraumatic peripheral nerve repair, atraumatic hernia repair, and suture line support in cardiovascular surgery. Each solution is designed to optimize tissue repair through controlled and reproducible procedures, using specialized delivery and activation devices intended to maximize product performance and ergonomics.
Founded in 2013, TISSIUM draws on groundbreaking research and a portfolio of intellectual property originating from the laboratories of Professor Robert Langer (MIT) and Professor Jeffrey M. Karp (Brigham and Women’s Hospital).
About Romain
After starting his career in investment banking, Romain joined TISSIUM in 2021 to lead its finance department. Before joining the company, he spent 11 years in corporate finance at ODDO BHF, where he most recently served as Managing Director and head of Public M&A/ECM France. He has advised on numerous market transactions, including IPOs, capital increases, delistings, tender offers, and other M&A transactions.
A more reliable capital structure
TISSIUM adopted Equify in 2021 to replace a capitalization table managed in Excel, which had become unreliable and prone to errors. The company’s growth and the increasing number of stakeholders made manual management both risky and time-consuming. The team wanted a solution that could ensure data reliability, streamline the tracking of its capitalization table, and provide greater transparency to its investors.
"With Excel, every change carried a risk of error. Equify has allowed us to move from rough management to reliable and traceable data."
Seamless attribution campaigns
Every year, TISSIUM conducts BSPCE grant campaigns for its employees. Before implementing Equify, these campaigns were carried out entirely by hand: preparing documents, sending personalized mailings, following up, and tracking signatures… It was a time-consuming, repetitive process that was particularly prone to errors. It kept the team busy for several weeks and had to be repeated exactly the same way every year, making it essential to implement a more reliable and automated process.
Now, beneficiaries sign their documents directly within the tool and can access them instantly in their personal account. Thanks to the integrated mail merge feature, the annual campaign can be managed with just a few clicks, with complete reliability. Automation offers two major benefits: legal standardization, achieved by using a single template for all beneficiaries, and significant time savings for the teams.
“We’ve transformed a cumbersome and repetitive annual administrative process into a seamless and secure operation. Each allocation is now standardized, traceable, and accessible with just a few clicks, allowing us to manage the entire allocation campaign from start to finish.”
Reliable and instantaneous data extraction
The ability to extract key data-such as the cap table, instruments to be allocated, and the securities transaction ledger-in just a few seconds is transforming the day-to-day work of teams. They can now respond immediately to investor reporting requests and close the books using completely reliable information.
This centralization eliminates the need for data re-entry, drastically reduces the risk of errors, and ensures consistent information for all stakeholders. Communication with investors becomes faster, more accurate, and more professional, freeing up time for tasks with higher added value.
"With Equify, we have a single source of truth. Data retrieval is instantaneous, which allows us to respond to investors in real time and close our accounts with complete reliability."
The Future with Equify
TISSIUM plans to expand the use of Equify to governance management, by directly managing general meetings from the platform. This development will enable the entire capital and governance lifecycle to be centralized within a single tool: from the capital table to stock awards, including general meetings and voting.
This integrated approach promises even greater efficiency and reliability in the company's management, simplifying processes and enhancing transparency for all stakeholders.
"Our goal is to centralize the entire capital lifecycle on Equify, from the capital table to general meetings. Having everything in one place ensures smooth and consistent management."
